AnGes, Inc. (4563.T)
JPY 78.0
(5.41%)
JPY 78.0
(5.41%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.78 Billion JPY | -66.77% |
| 2022 | 8.39 Billion JPY | 23.08% |
| 2021 | 6.82 Billion JPY | 20.2% |
| 2020 | 5.67 Billion JPY | 1109.36% |
| 2019 | 469.25 Million JPY | 48.4% |
| 2018 | 316.21 Million JPY | -7.47% |
| 2017 | 341.72 Million JPY | -48.98% |
| 2016 | 669.81 Million JPY | 26.23% |
| 2015 | 530.63 Million JPY | 18.16% |
| 2014 | 449.08 Million JPY | 24.53% |
| 2013 | 360.63 Million JPY | -30.87% |
| 2012 | 521.67 Million JPY | -15.62% |
| 2011 | 618.21 Million JPY | -13.72% |
| 2010 | 716.49 Million JPY | 10.36% |
| 2009 | 649.21 Million JPY | -9.15% |
| 2008 | 714.62 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.19 Billion JPY | -26.15% |
| 2024 Q1 | 2.97 Billion JPY | 6.72% |
| 2023 Q1 | 8.49 Billion JPY | 1.22% |
| 2023 Q2 | 8.9 Billion JPY | 4.77% |
| 2023 FY | 2.78 Billion JPY | -66.77% |
| 2023 Q4 | 2.78 Billion JPY | -53.14% |
| 2023 Q3 | 5.95 Billion JPY | -33.14% |
| 2022 Q3 | 7.06 Billion JPY | -12.56% |
| 2022 Q2 | 8.07 Billion JPY | 12.19% |
| 2022 Q1 | 7.2 Billion JPY | 5.58% |
| 2022 FY | 8.39 Billion JPY | 23.08% |
| 2022 Q4 | 8.39 Billion JPY | 18.84% |
| 2021 Q2 | 7.7 Billion JPY | 35.31% |
| 2021 Q3 | 7.92 Billion JPY | 2.76% |
| 2021 Q4 | 6.82 Billion JPY | -13.9% |
| 2021 FY | 6.82 Billion JPY | 20.2% |
| 2021 Q1 | 5.69 Billion JPY | 0.4% |
| 2020 FY | 5.67 Billion JPY | 1109.36% |
| 2020 Q3 | 1.01 Billion JPY | 132.8% |
| 2020 Q2 | 437.03 Million JPY | 32.5% |
| 2020 Q4 | 5.67 Billion JPY | 457.79% |
| 2020 Q1 | 329.83 Million JPY | -29.71% |
| 2019 Q4 | 469.25 Million JPY | 27.66% |
| 2019 FY | 469.25 Million JPY | 48.4% |
| 2019 Q1 | 256.58 Million JPY | -18.86% |
| 2019 Q2 | 245.06 Million JPY | -4.49% |
| 2019 Q3 | 367.58 Million JPY | 50.0% |
| 2018 Q3 | 357.08 Million JPY | -11.73% |
| 2018 Q1 | 183.7 Million JPY | -46.24% |
| 2018 Q2 | 404.51 Million JPY | 120.2% |
| 2018 FY | 316.21 Million JPY | -7.47% |
| 2018 Q4 | 316.21 Million JPY | -11.45% |
| 2017 Q2 | 259.11 Million JPY | -53.97% |
| 2017 FY | 341.72 Million JPY | -48.98% |
| 2017 Q4 | 341.72 Million JPY | -55.39% |
| 2017 Q3 | 766.07 Million JPY | 195.64% |
| 2017 Q1 | 562.91 Million JPY | -15.96% |
| 2016 Q3 | 451.16 Million JPY | -40.29% |
| 2016 Q1 | 781.26 Million JPY | 47.23% |
| 2016 FY | 669.81 Million JPY | 26.23% |
| 2016 Q4 | 669.81 Million JPY | 48.46% |
| 2016 Q2 | 755.61 Million JPY | -3.28% |
| 2015 Q1 | 460.45 Million JPY | 2.53% |
| 2015 FY | 530.63 Million JPY | 18.16% |
| 2015 Q3 | 717.03 Million JPY | -6.86% |
| 2015 Q2 | 769.81 Million JPY | 67.18% |
| 2015 Q4 | 530.63 Million JPY | -26.0% |
| 2014 Q1 | 335.23 Million JPY | -7.04% |
| 2014 Q4 | 449.08 Million JPY | -35.04% |
| 2014 Q3 | 691.26 Million JPY | 29.13% |
| 2014 Q2 | 535.33 Million JPY | 59.69% |
| 2014 FY | 449.08 Million JPY | 24.53% |
| 2013 Q2 | 601.08 Million JPY | 23.65% |
| 2013 Q3 | 556.68 Million JPY | -7.39% |
| 2013 Q4 | 360.63 Million JPY | -35.22% |
| 2013 FY | 360.63 Million JPY | -30.87% |
| 2013 Q1 | 486.12 Million JPY | -6.81% |
| 2012 Q4 | 521.67 Million JPY | -11.05% |
| 2012 Q3 | 586.44 Million JPY | 2.54% |
| 2012 Q2 | 571.93 Million JPY | -10.39% |
| 2012 Q1 | 638.23 Million JPY | 3.24% |
| 2012 FY | 521.67 Million JPY | -15.62% |
| 2011 FY | 618.21 Million JPY | -13.72% |
| 2011 Q3 | 571.82 Million JPY | -28.13% |
| 2011 Q2 | 795.6 Million JPY | 15.76% |
| 2011 Q4 | 618.21 Million JPY | 8.11% |
| 2011 Q1 | 687.28 Million JPY | -4.08% |
| 2010 Q2 | 765.37 Million JPY | 0.71% |
| 2010 Q1 | 759.99 Million JPY | 17.06% |
| 2010 FY | 716.49 Million JPY | 10.36% |
| 2010 Q3 | 666.72 Million JPY | -12.89% |
| 2010 Q4 | 716.49 Million JPY | 7.46% |
| 2009 Q3 | 701.18 Million JPY | -0.12% |
| 2009 FY | 649.21 Million JPY | -9.15% |
| 2009 Q2 | 702.05 Million JPY | -11.55% |
| 2009 Q1 | 793.72 Million JPY | 0.0% |
| 2009 Q4 | 649.21 Million JPY | -7.41% |
| 2008 FY | 714.62 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 14.092% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -4298.872% |
| GNI Group Ltd. | 26.34 Billion JPY | 89.411% |
| Linical Co., Ltd. | 10.3 Billion JPY | 72.932% |
| Trans Genic Inc. | 3.81 Billion JPY | 26.837% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -372.611% |
| Soiken Holdings Inc. | 697.02 Million JPY | -300.183% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 7.66% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -443.094% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 96.914% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -689.583% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | -69.064% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -490.524% |
| CanBas Co., Ltd. | 91.98 Million JPY | -2932.318% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | -155.062% |
| RaQualia Pharma Inc. | 809.83 Million JPY | -244.439% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -369.803% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 34.431% |
| PeptiDream Inc. | 29.11 Billion JPY | 90.419% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -392.386% |
| Ribomic Inc. | 155.8 Million JPY | -1690.249% |
| SanBio Company Limited | 2.25 Billion JPY | -23.703% |
| Healios K.K. | 11.28 Billion JPY | 75.285% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -1010.113% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -655.927% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -1055.033% |
| StemRIM | 187 Million JPY | -1391.641% |
| CellSource Co., Ltd. | 677.73 Million JPY | -311.57% |
| FunPep Company Limited | 189.32 Million JPY | -1373.331% |
| Kringle Pharma, Inc. | 596.95 Million JPY | -367.266% |
| Stella Pharma Corporation | 1.44 Billion JPY | -93.222% |
| TMS Co., Ltd. | 97.68 Million JPY | -2755.356% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -2948.691% |
| Cuorips Inc. | 200.96 Million JPY | -1288.015% |
| K Pharma,Inc. | 209.13 Million JPY | -1233.771% |
| Takara Bio Inc. | 11.42 Billion JPY | 75.575% |
| ReproCELL Incorporated | 741.03 Million JPY | -276.417% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | -203.948% |
| StemCell Institute Inc. | 3.85 Billion JPY | 27.558% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | -207.053% |
| CellSeed Inc. | 301.04 Million JPY | -826.556% |